Figure 3
FAK expression and E-cadherin loss are associated with adverse events and lymph node metastasis, respectively. A, FAKc high (score ≥ 2 in >10% tumor area) cases have a significantly higher proportion of adverse events (tumor recurrence/2nd primary tumor: 9/10) than FAKc low cases (16/36, p = 0.0105). B, Membranous E-cadherin(+) cases (score 3 in >10% tumor area) have a significantly lower proportion of lymph node metastases (5/17) than E-cadherin(-) cases (21/29, p = 0.0064).